Inovio Pharmaceuticals Inc. shares advanced 3.82% to $6.80 Monday. This proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.38% to 13,379.05 and Dow Jones Industrial Average DJIA falling 0.16% to 34,327.79. This was the stock’s second consecutive day of gains.
Inovio Pharmaceuticals Inc. closed $26.99 below its 52-week high ($33.79), which the company reached on June 26th. The stock outperformed some of its competitors Monday, as AbbVie Inc. ABBV rose 0.40% to $116.89, Amgen Inc. AMGN rose 0.40% to $252.38, and AstraZeneca PLC ADR AZN rose 1.21% to $55.88. Trading volume (5.0 M) remained 4.5 million below its 50-day average volume of 9.4 M.
Dr Dansey previously served as the Therapeutic Area Head for Late-Stage Oncology at Merck & Co., Inc., he oversaw registration efforts for Keytruda® across multiple tumor types. He was the Vice President of Oncology Clinical Research at Gilead Sciences and the Global Development Lead for Xgeva® at Amgen, where he held multiple roles in both oncology and haematology. Dr Dansey holds an M.D. from the University of Witwatersrand in Johannesburg, South Africa.